Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7216 to 7230 of 7707 results

  1. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE diagnostics guidance 44.  

    Diagnostics guidance
    Published
    28 November 2012

  2. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Evidence summary
    Published
    2 July 2013

  3. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Evidence summary
    Published
    23 July 2013

  4. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    13 October 2015

  5. Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    16 September 2014

  6. Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    6 November 2014

  7. Type 1 diabetes: insulin degludec (ESNM5)

    This evidence summary has been updated and replaced by NICE advice ESNM24.

    Evidence summary
    Published
    2 November 2012

  8. Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

    This evidence summary has been updated and replaced by NICE guideline NG203.

    Evidence summary
    Published
    6 January 2015

  9. Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    27 January 2015

  10. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7)

    This evidence summary has been updated and replaced by NICE guideline NG217.

    Evidence summary
    Published
    14 December 2012

  11. Attention deficit hyperactivity disorder in children and young people: guanfacine prolonged-release (ESNM70)

    This evidence summary has been updated and replaced by NICE guideline NG87.

    Evidence summary
    Published
    22 March 2016

  12. Moderate to severe acute post­-operative pain: sufentanil sublingual tablet system (ESNM71)

    This evidence summary has been withdrawn because the product is no longer available in the UK.

    Evidence summary
    Published
    30 March 2016

  13. Chronic obstructive pulmonary disease: tiotropium/olodaterol (Spiolto Respimat) (ESNM72)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    10 May 2016

  14. Chronic obstructive pulmonary disease: olodaterol (ESNM54)

    This evidence summary has been updated and replaced by NICE guideline 115.

    Evidence summary
    Published
    3 February 2015

  15. Asthma: tiotropium (Spiriva Respimat) (ESNM55)

    This evidence summary has been updated and replaced by NICE guideline NG80.

    Evidence summary
    Published
    3 March 2015